logo
Plus   Neg
Share
Email

Regulus Therapeutics, Bio-Techne Partner For Biomarker Development - Quick Facts

Bio-Techne Corp. (TECH) and Regulus Therapeutics Inc. (RGLS) announced Wednesday a collaboration to support Regulus with biomarker analysis for the clinical development of RGLS4326, an Autosomal Dominant Polycystic Kidney Disease (ADPKD) treatment.

Regulus has utilized two Bio-Techne branded product lines, ProteinSimple and Exosome Diagnostics, to aid in their clinical trial patient testing.

RGLS4326 is a first in class anti-miR-17 therapy currently in Phase 1b clinical development in ADPKD patients. The Phase 1b trial is an adaptive design, open-label, multiple dose study in up to three cohorts of patients with ADPKD.

This study will evaluate RGLS4326 for safety, pharmacokinetics, and pharmacodynamic effects on the levels of polycystin 1 (PC1) and polycystin 2 (PC2). It is designed to assess whether different dose levels of RGLS4326 can increase levels of PC1 and PC2 in ADPKD patients.

The first cohort is expected to enroll up to nine patients who will receive RGLS4326 every two weeks over a six-week period. The Company anticipates availability of results from the first cohort by the end of first quarter of 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The United Kingdom's Competition and Markets Authority (CMA) has launched an investigation into technology giant Apple Inc. (AAPL) following complaints that its terms and conditions for app developers are unfair and anti-competitive. iPhone maker Apple also operates the App Store, which is the only... Supermarket chain Kroger Co. on Thursday reported that it posted a loss for the fourth quarter compared to a profit last year, hurt by pension plan withdrawal liabilities. Adjusted earnings per share topped analysts' estimates, while quarterly revenues missed it. However, the company initiated adjusted earning guidance for the full-year 2021, well above analysts' estimates. Retail sales are projected to grow at a potentially record rate during 2021, but the ongoing COVID-19 pandemic remains the biggest challenge for the year, according to the National Retail Federation. "There is no doubt the economy is positioned for growth in 2021, but how much growth comes down to a single non-economic force - the coronavirus," NRF Chief Economist Jack Kleinhenz said.
Follow RTT